Over the years, a host of large drugmakers have inked settlements with the federal authorities to resolve allegations that ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

Once again, several members of Congress have come together to call for an end to the tax deductions that drugmakers receive ...

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the ...

Pfizer is raising the bar for its sweeping cost-savings drive yet again, this time cranking up the total target to $7.7 ...

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

Persistence has paid off for Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).

Novartis has a lot cooking with new drug launches, and the company is not letting potential U.S. tariffs on pharmaceuticals ...

Bayer has overturned a ruling that it brought discredit on the pharma industry. | Bayer has overturned a ruling that it ...

A paper published this month in the journal Current Addiction Reports discusses the merits of intranasal medications that can ...

For the second year in a row, the pharmaceutical industry has dipped further out of favor with patient groups around the world. | For the second year in a row, the pharmaceutical industry has dipped ...